Advertisement

Topics

ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial

08:30 EST 6 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Outcome of DSMB Interim Efficacy Analysis Anticipated in the Third Quarter of 2017 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targ...

Other Sources for this Article

ARCA biopharma, Inc.
Investor & Media Contact:
Derek Cole, 720-940-2163
derek.cole@arcabio.com

NEXT ARTICLE

More From BioPortfolio on "ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial"

Advertisement
Quick Search
Advertisement
Advertisement